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Syndekaanit ovat solukalvon heparaanisulfaatti-proteoglykaaneja, jotka toimivat ko-reseptoreina 
kasvutekijöille, sytokiineille ja morfogeeneille ja ovat tärkeitä solunsisäisessä signaloinnissa.  Niitä on lähes 
jokaisen solutyypin pinnalla ja ne säätelevät niin normaalien kuin patologistenkin tilojen kehitystä.  
Syndekaaneja on neljää eri tyyppiä, joista syndekaani-4 toimii tärkeänä säätelijänä solujen migraatiossa. Sitä 
esiintyy eniten fibroblastien ja epiteelisolujen pinnalla. Syndekaani-4 säätelee fysiologista kudosten 
paranemista ja angiogeneesiä, mutta myös patologista tuumorikasvua. 
Syndekaani-4:sta koodaava SDC4-geeni on yhdistetty useisiin ihmisten syöpiin, mutta sen vaikutuksesta 
tuumorin muodostumisessa ja kasvussa ei ole suoraa näyttöä. ”Syndekaani-4 kokeellisessa 
ihosyöpämallissa”- tutkimuksen tarkoitus oli selvittää SDC4:n vaikutusta tuumorikasvuun ihon 
epidermaalisessa karsinogeenimallissa. 
Tutkimuksessa käytettiin SDC4-poistogeenisiä sekä villityypin hiiriä, joiden selkä käsiteltiin ensin 
karsinogeenillä (DMBA) ja sitten kahdesti viikossa 21 viikon ajan kasvua kiihdyttävällä aineella (TPA). 
Syntyneet papilloomat laskettiin ja niiden koko ja kasvu mitattiin tarkasti. 
SDC4-geenin poisto ei vaikuttanut siihen, kuinka nopeasti papilloomia alkoi kehittymään. Poistogeenisillä 
hiirillä ilmeni kuitenkin neljä kertaa vähemmän papilloomia ja ne olivat kymmenen kertaa pienempiä kuin 
villityypin hiirillä.  
Tutkimus osoittaa, että SDC4-geenillä on merkittävä rooli tuumorikasvussa. 
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1 SYNDEC1AN-4 PROMOTES TUMOR GROWTH IN 
CARCINOGEN-INDUCED SKIN CANCER MODEL  
 
 
 
1.1 Abstract 
 
The syndecan-4 (SDC4) gene encodes transmembrane heparan sulfate proteoglycans 
that act as receptors for extracellular matrix molecules and co-receptors for growth 
factors, cytokines, and morphogens. Despite the SDC4 been implicated for promoting 
tumour progression in wide variety of different human cancers, no direct evidence on 
its role in tumour progression exists. Using mice with a deletion of the SDC4 gene 
(SDC KO), we found that SDC4 facilitates DMBA/TPA-induced skin tumour 
growth. The tumours appeared in wild-type (WT) mice at the same rate as in SDC4 
KO mice, but WT mice developed almost 4 times more tumours and almost 10 times 
more large papillomas than SDC4 KO mice. We provide first direct evidence that 
SDC4 is indeed needed for tumor growth by showing that it is pro-tumourigenic in 
the DMBA/TPA tumour model. 
 
 
1.2 Introduction 
 
Syndecans are transmembrane heparan sulfate proteoglycans that act as receptors for 
extracellular matrix (ECM) molecules and co-receptors for growth factors, cytokines, 
and morphogens (1-3). They are present in almost all cell types and tissues and they 
act as regulators not only in normal but also in pathological conditions (1-3). There 
are four vertebrae syndecans (SDCs), SDC1-4, each with large heparan sulfate and 
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chondroitin sulfate chains covalently attached to the extracellular domain and short 
cytoplasmic tails that interact with a number of signaling adaptors and enzymes (1-3). 
The fibronectin receptor syndecan-4 (SDC4) regulates GTPase activity and adhesive 
function to modulate cell migration (4,5). It is ubiquitously expressed, most notably 
in fibroblast, and its defect leads to impaired wound healing due to migration and 
angiogenesis defects (5-7). 
The heparan sulfate (HS) side chains of the SDCs bind to a plethora of proteins, 
including chemokines and cytokines (∼60) and growth factors and morphogens that 
play essential roles in cancer progression and tissue repair (∼50); blood coagulation 
factors such as serine proteases and their inhibitors (∼25); structural ECM proteins 
such as collagens, fibronectin, and vitronectin (∼25); proteins involved in the 
complement pathways (∼20); single-transmembrane signaling receptors (∼15); and 
cell adhesion proteins (∼10) (2). The interaction of SDCs with growth factors and 
their respective receptors has been characterized in great detail (1-3). Because of the 
high negative charge in HS side chain of the SDCs, the initial contact heparin binding 
growth factors make with the cells is by binding to the HS chains (1-3). The HS chain 
acts as a template that bridges growth factor and its receptor together. Formation of 
the complex effectively lowers the concentration of growth factor required to initiate 
signalling through its receptor and extends the duration of the response (1-3). Thus, it 
is not striking that SDCs have been implicated to regulate not only the physiological 
tissue repair but also the pathological tumour growth (3,5,8). 
Due to its essential role in mediating the growth stimulatory signal provided by 
multiple growth factors and its rapid expression at the onset of tumor formation in 
various forms of cancer (1-3,5,8), SDC4 has been implicated in the pathogenesis of 
wide variety of human cancers (8). However, there is no direct evidence that SDC4 
indeed promotes tumour formation (8), a point highlighted by the fact that the 
redundancy of an individual SDC gene has no critical role during development (6,7). 
Thus, we decided to study whether carcinogen-initiated tumour formation is 
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dependent of SDC4 by exploring the role of SDC4 in a skin epidermal carcinogenesis 
model (two-stage DMBA/TPA model) in wild-type (WT) and SDC4 knockout mice 
(SDC4 KO). 
 
 
1.3 Methods 
 
1.3.1 Mice 
The generation of syndecan-4 mice have been described in detail elsewhere (7). The 
mice were obtained from the laboratory of Mark Bass (University of Bristol, Bristol, 
UK). Before any experiments, syndecan-4 KO mice were backcrossed eight 
generations with C57BL/6 strain (Harlan) to obtain syndecan-4 expressing (wild-
type, WT) and syndecan-4 KO strain in the same background genetic strain of mice 
(littermates). Then homozygous syndecan-4 KO animals were bred. The genotype 
was determined in each animal by PCR. Mice were fed with standard laboratory 
pellets and water ad libitum. All animal experiments were performed in accordance 
with protocols approved by the National Animal Ethics Committee of Finland. 
 
1.3.2 Skin tumour induction 
Syndecan-4 KO and C57BL/6 WT mice were treated with DMBA and TPA to induce 
skin tumours according to the established protocol (9,10). In brief, the backs of 8-
week-old mice were shaved and 24h later 50 µg DMBA (7,12-
Dimethylbenz[a]anthracene) (Sigma, Dorset, UK) in 200 µl acetone was applied 
topically on the shaved area of the dorsal skin. After a week, the back skin of the 
mice was treated twice a week with 5 µg TPA (12-O-tetradecanoylphorbol-13-
acetate) (Sigma) in 200 µl acetone for 21 weeks (10). Tumours (1 mm in diameter or 
larger) were counted twice a week. The fur excluding tumours was carefully shaved 
every two weeks. 
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1.3.3 Immunohistochemical (IHC) and TUNEL staining 
Samples of back skin from sacrificed, shaved control mice or mice at week 21 of the 
tumour induction experiment were collected and fixed with 4% paraformaldehyde 
and embedded in paraffin according to standard protocols. Hematoxylin/eosin 
staining and DAB immunohistochemical staining (IHC) was performed on 6 µm 
thick paraffin sections. The IHC stainings were carried out essentially as described 
previously (10). Briefly, the following primary antibodies were used for IHC 
(according to the manufacturer’s instructions): M7249 TEC-3 rat anti-Ki67 and 
A0452 rabbit anti-CD3 (DakoCytomation, Glostrup, Denmark), 550274 rat anti-
CD31 (BD Pharminogen, Oxford, UK), 68672 rabbit anti-neutrophil elastase 
(AbCam, Cambridge, UK) and MF48000 BM8 rat anti-F4/80 (Life Technologies 
Ltd., Paisley, UK) (10). The blocking reagents used for IHC were S2O23 REAL and 
S0809 Antibody Diluent (Dako).  In the case of blocking prior to CD3 or neutrophil 
elastase staining, G9023 goat serum or A4503 BSA (Sigma) were used respectively, 
at 5% in PBS. The horseradish peroxidase (HRP) conjugated secondary antibody 
reagents used were: PO448 goat anti-rabbit (Dako), 414311F anti-rat Histofine 
(Nichirei Bio, Tokyo, Japan) and for neutrophil elastase staining RMR622 Rabbit on 
Rodent (Biocare Medical, Concord, CA, USA). XMF963 XM-Factor (Biocare) was 
used to block before secondary staining with Rabbit on Rodent. Peroxidase reactive 
chromogens used were K3465 DAB (DAKO) and RAEC810 Romulin AEC 
(BioCare). Immunohistochemical TUNEL staining for apoptotic nuclei was 
performed using the K403-50 TUNEL IHC Kit (Biovision, Milpitas, CA, USA) with 
Methyl Green nuclear counter stain, as described previously (10).  
 
1.3.4 Quantitative analysis of immunostaining and histochemical staining 
All slides were scanned using the Aperio ScanScope® CS and XT systems (Aperio 
Technologies Inc., California, USA) (10,18). Slides were viewed and analysed 
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remotely using desktop personal computers employing the web-based ImageScope™ 
viewer. The Spectrum digital pathology system analysis algorithm package and 
Image Scope analysis software (version 9; Aperio Technologies Inc.) were applied to 
quantify immunohistochemical signal. These algorithms calculate the area of positive 
staining, the average positive intensity (optical density), as well as the percentage of 
weak (1+), medium (2+), and strong (3+) positive staining (10,18). All quantified 
histochemical analyses (Ki-67, CD31, F4/80, CD3, TUNEL and M2-macrophages) 
were performed according to the protocols used to established these algorithms for 
each respective staining (10,18). 
 
1.3.5 Flow cytometry 
The skin draining lymph nodes (dLN) and spleens were collected immediately after 
the sacrifice of the animal and tissues were placed in ice-cold PBS. For surface 
markers, the dLN and spleen cells were stained with antibodies against mouse CD4, 
CD8, CD44, CD62L and CD69 (all from eBioscience). For intracellular staining, 
isolated dLN cells were stimulated with PMA and Ca-ionomycin for 4 hours, and 
Brefeldin A and Monensin were applied for the last 2 hours of the stimulation. The 
cells were stained with surface markers and subsequently fixed overnight with 
Fixation/Permeabilization solution (from Foxp3/Transcription Factor Staining Buffer 
Set, eBioscience), permeabilized with Permeabilization Buffer (eBioscience) and 
stained with intracellular antibodies (IL-10, IFNγ, IL-17A, Foxp3; all from 
eBioscience), according to the manufacturer’s instructions. All cells were analysed 
with FACSCanto II (Becton Dickinson) instrument. Data analysis was performed 
with FlowJo software (Flowjo LLC, Ashland, OR, USA). 
 
1.3.6 Statistical analysis 
Mean averages are shown with 95% confidence intervals. All data were analysed to 
determine if it was normally distributed (D'Agostino & Pearson omnibus and 
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Shapiro-Wilk normality tests). Significance at a given time point was calculated by 
two-tailed Student’s t-test for normally distributed data. An alpha level less than 0.05 
was considered significant. Survival plot data were analysed by log-rank (Mantel-
Cox) test and non-normally distributed time course data were analysed by non-linear 
regression. Prism 6 (GraphPad Software, La Jolla California, USA) was used for a 
majority of the analyses and STATA 13 (StataCorp LP, College Station, Texas, 
USA:) statistical analysis software was used for non-linear regression analysis, as 
indicated. 
 
 
 
1.4 Results 
 
1.4.1 SDC4 plays an important role in skin tumour growth 
To investigate the role of SDC4 in skin tumour formation, we treated the back skin of 
adult mice deficient for SDC4 gene expression (SDC4 KO) and wild-type mice (WT, 
as control) once with a local application of the mutagen DMBA, and then repeatedly 
with the growth-promoting  TPA, twice weekly for a period of 21 weeks. This 
treatment induces papillomas derived from the interfollicular epidermis (9,10).  
The first papillomas were observed both in the WT and SDC4 KO mice 9 weeks after 
the beginning of the DMBA/TPA treatment, and after 12 and 13 weeks, none of the 
animals were tumour-free (Figure 1a). No difference was detected in the “tumour-
free” survival time between SDC4 KO and WT mice (Figure 1a). However, the 
tumours were incident in SDC4 WT animals at a rate on average threefold greater 
than in KO mice during the course of experiments (negative binominal regression 
analysis: incidence rate ratio (IRR)= 0.00; 95% confidence interval (CI) 0.00, 0.00). 
At the end of the experiments (21 weeks of DMBA/TPA treatment), SDC4 WT 
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animals had on average almost 3.5 times more tumours than the KO mice (Figure 1a-
d). Furthermore, majority of tumours grew into large papillomas (> 2 mm in size) in 
SDC4 WT mice, whereas the large papillomas were very rare in SDC4 KO mice (Fig. 
). Almost 10-fold more large papillomas were identified in the SDC4 WT than in the 
KO mice (Fig. ).  
 
1.4.2 SDC4 expression is ….. 
We confirmed the total lack of SDC4 protein in the SDC4 KO mice by 
immunohistochemistry both in untreated and DMBA/TPA-treated skin samples 
(Figure 2a). We detected very strong expression of SDC4 protein in the epidermal 
cell layer either in untreated or DMBA/TPA-treated WT mice (Figure 2b). Blood 
vessels also expressed SDC4 protein in the WT…. 
1.4.3 The resistance of R-Ras KO mice to skin tumourigenesis is not associated with decreased 
vascularisation 
To understand the mechanism of the tumour-promoting function of R-Ras in the skin, 
we continued to analyse the whole skin by determining the epidermal and dermal 
thickening, and the amount of vasculature (angiogenesis) in the back skin of 
DMBA/TPA treated and untreated mice. All analyses were performed from the same 
part of the back skin in all animals to avoid any bias (such as selecting a plane of 
analyses to go through tumour). 
In untreated mice, loss of SDC4 had minor effects on epidermal and dermal 
thicknesses, as the SDC4 KO mice had a slightly thinner epidermis and thicker 
dermis than the WT littermates (P <  and P < respectively, Supplementary Figure S2). 
Treatment with DMBA/TPA induced a substantial increase (P < 0.001) and 
approximate doubling in both dermal and epidermal thickness in both genotypes; 
both epidermis (P <) and dermis (not significant) being apparently substantially 
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thicker in the WT mice (the analysis was performed only from areas devoid of 
papillomas) than in the SDC4 KO mice (Supplementary Figure S2). 
As the availability of vascular supply is a limiting factor for tumour growth and 
SDC4 is implicated in processes involving vascular defects in fetal placental 
labyrinth and poor angiogenic response in postnatal wound healing (6). 
 
1.4.4 Skin draining lymph node and spleen T cell populations are not different between SDC4 
KO and WT mice  
To gain more information on the T lymphocyte (helper, cytotoxic or regulatory T 
cells; memory and activation status), myeloid and B cell populations, the skin 
draining lymph node (dLN) and spleen cells from SDC4 KO mice and their WT 
littermate controls were subjected to flow cytometric analysis after the 21-week 
DMBA/TPA treatment. CD4+ (T helper cells) and B cells are known to be crucial for 
the development of tumours in DMBA/TPA-model (11,12), whereas CD8+ 
(Cytotoxic T cells) cells inhibit the tumour development in the model (11). There 
were no differences in any of the analysed T cell, myeloid or B cell populations in the 
spleen (Fig.). There were no significant differences in the total CD4+ and CD8+ T 
cell percentages (of total live cells) in the dLNs between the SDC4 KO and WT mice 
treated with DMBA/TPA for 21 weeks (Fig.) Then we analysed the memory 
phenotypes (central memory T cells, effector memory T cells, naïve T cells) of spleen 
and dLN T cells by using CD44 and CD62L antibodies and flow cytometry. There 
were no differences in the different memory T cell populations in the spleen (Fig. ), 
but there were substantially more both CD4+ CD62LlowCD44high (P=0.057; not 
significant), CD8+ CD62LlowCD44high (P=0.017) as well as slightly more CD8+ 
CD62LhighCD44high (P=0.069; not significant) cells in the dLNs in the SDC4 KO than 
in the WT mice (Fig.). However, there were no differences in the number of recently 
activated T cells, as the same proportion of both CD4+ and CD8+ T cells from the 
KO and the WT animals were positive for CD69 (Fig. ). Neither were there were any 
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differences identified in myeloid or B cell populations in the dLNs between SDC4 
WT and KO mice (Fig.).   
The percentage of regulatory T cells (Tregs) was assessed by staining the dLN cells 
with antibodies against CD25 and Foxp3, and performing flow cytometric analysis. 
There were no differences in the number of Treg cells in the dLNs of SDC4 KO mice 
compared to those of WT littermates from mice treated with DMBA/TPA for 21 
weeks (Fig. 3).  
In conclusion, the treatment of mice with DMBA/TPA for 17 weeks does not have an 
effect on the numbers of the skin draining lymph node T cells, although…. 
 
1.4.5 No differences in the T cell-derived tumour promoting cytokines during tumour 
development 
It is an established fact that tumourigenesis in the DMBA/TPA model is highly 
dependent upon the induction of acute inflammation (13). To investigate tumour 
promoting cytokine production of T cells in the tumour development in the SDC4 KO 
mice, we analysed dLN T cells by intracellular staining and flow cytometry. We 
focused on pro-inflammatory interferon gamma (IFNγ) and interleukin (IL) 17A (IL-
17A) and IL-10. Both IFNγ and IL-17A, in particular, are known to be pro-
tumourigenic in the DMBA/TPA model (14-17) and inflammatory cell produced IL-
10 has been implicated in the pathogenesis of the model (11). There were no 
differences in the percentage of CD8+, Tregs nor CD4+ effector cells producing IFNγ 
and IL-17A in the dLNs of SDC4 KO and WT mice and there was no difference in 
the production of CD4+ T cell-produced IL-10 (Fig. ).  
 
 
1.5 Discussion 
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In summary, our study shows an important role of the SDC4 in epidermal hyperplasia 
and tumour growth in a skin carcinogenesis-tumour model. Our finding is novel in 
the sense that SDC4 has not been directly shown to promote tumour progression 
previously (Figure 2). Our finding is also somehow an unexpected outcome, as SDC4 
has so far been redundant in majority of biological processes in has been studied (7).  
On the other hand, SDC4 is an important receptor for large number of heparin 
binding growth factors that are crucial for tumour growth. One could also make an 
argument that is kind of natural that a lack of important receptor for large number of 
cytokines, chemokines and growth factors should inhibit the progression of cancer in 
the model that requires large variety of such diverse biological processes as 
inflammation, angiogenesis, migration and transformation to be involved for tumours 
to grow. 
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Angiogenesis is a hallmark and exacerbating factor in cancer and neovascular eye 
diseases. Significant efforts have been made to control this process for therapeutic 
benefit, most notably by targeting the key angiogenic growth factor, vascular 
endothelial growth factor-A (VEGFA) and its receptor VEGFR2. Here, we report a 
new fundamental role for Syndecan-4 (SDC4) in VEGFA-driven pathological 
neovascularisation. The SDC4 null mouse (Sdc4-/-) exhibited reduced tumorigenesis 
and delayed wound healing in the eye due to impaired angiogenesis. We establish that 
this results from a failure to respond to VEGFA, and demonstrate that SDC4 is required 
for VEGFR2 signalling. We further show that blockade of VEGFA-driven 
neovascularisation can be achieved using a soluble form of SDC4. These findings 
establish a molecular framework coupling SDC4 with pathological angiogenesis, 
which may prove significant for the development of future anti-angiogenic therapeutic 
applications.  
 
 
2.2 Main text 
 
The formation of new blood vessels from pre-existing ones (angiogenesis) is a critical 
developmental process and is an important component of physiological tissue 
regeneration1. In cancer, inflammatory disorders and neovascular eye diseases, 
angiogenesis is a key feature in the pathogenesis and significant efforts have been made 
to control this process for therapeutic benefit2-5. The pro-angiogenic chemokine 
vascular endothelial growth factor A (VEGFA) and its receptor VEGFR2 are the major 
drivers of angiogenesis in these pathologies and drugs targeting this axis have been 
used with substantial success in the clinic. However, there are issues of patient non-
response, resistance to therapy and several side effects that are associated with 
 14 
 
VEGFA/VEGFR2 targeting drugs6, 7, highlighting the need for better understanding of 
the underlying molecular basis of pathological angiogenesis.  
There is considerable evidence to suggest a role for heparan sulfate proteoglycans 
(HSPGs) in VEGFA signaling. HSPGs are abundant cell surface and matrix molecules 
that influence cell responses to growth factors as well as the distributions of 
chemokines and morphogens in tissues 8, 9. VEGFA binds to heparan sulfate (HS) with 
high affinity10, and cells where HS has been enzymatically removed have abrogated 
VEGFA signalling11. VEGFR2 also binds to HS, suggesting that HSPGs may facilitate 
the formation of an active signalling complex12. Thus, HSPGs are implicated as 
important co-receptors and regulators of VEGFA gradients. The interaction between 
VEGFA and HSPGs is largely through the glycosaminoglycan part of the molecule10, 
11 though the identity and the role of a specific HSPG core protein has remained elusive. 
The syndecans are a four-member family of transmembrane HSPGs with diverse roles 
in cell adhesion, receptor trafficking and growth factor signalling13, 14. Roles in 
angiogenesis have also been proposed; for example, regulatory sequences in both the 
syndecan-1 and -2 ectodomains can inhibit this process via distinct pathways15-17. 
Syndecan-4 null mice (Sdc4-/-) exhibit defects in the development of the foetal 
labyrinth and in granulation tissue formation after wounding18, 19 which is suggestive 
of a role in new blood vessel formation. We have therefore investigated whether an 
individual HSPG has a role in disease models where angiogenesis is a feature. 
 
2.2.1 Sdc4-/- animals are protected in tumor models by reduced angiogenesis 
The formation of new blood vessels is an essential component of tumor growth and 
progression20 and we observed that in a skin epidermal carcinogenesis model (two 
stage DMBA/TPA), tumor incidence and size were greatly reduced in Sdc4-/- mice 
compared to wild-type (WT) animals, although the tumor-free survival was almost 
identical (fig. S1). WT animals had considerably more papillomas (2.3x) than Sdc4-/- 
mice at the end of the experiment (week 19) and, in particular, larger tumors (> 2 mm) 
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were significantly more prevalent in WT animals (Fig. 1A-C). To dissect whether this 
phenotype is due to Sdc4-/- tumor cells or Sdc4-/- tumor vasculature, we injected 
B16F1 melanoma cells, which express SDC4 (fig. S2A), into the flank of WT and 
Sdc4-/- mice. Mice were sacrificed after 2 weeks and both tumor volume and weight 
were greatly reduced in Sdc4-/- animals when compared to WT controls (Fig. 1D and 
E, fig. S2C and D). This suggested that tumor angiogenesis was compromised in Sdc4-
/- mice. 
A recent study using a Lewis lung carcinoma model concurred with our findings that 
tumor volume was greatly reduced in in Sdc4-/- animals but correlated with an 
increased number of Natural killer (NK) cells in immune infiltrates from tumors21. This 
prompted us to analyze the immune infiltrates from B16F1 tumors and spleens from 
healthy mice. This revealed no differences in the number of NK cells between WT and 
Sdc4-/- animals (Fig. 1F and G) and this was also true of other leukocytes subsets 
including B cells, T cells, monocytes and neutrophils (fig. S3A and B). Analysis of 
skin and tumors from the DMBA/TPA model also showed no trend for differential 
inflammatory responses, i.e. macrophages, T cells or neutrophils, between WT and 
Sdc4-/- animals (fig. S4A-F).  
Importantly, histological analysis of B16F1 tumor sections from WT animals revealed 
vascular structures with, in many cases, a well-defined lumen (white arrows in Fig. 
1H). In Sdc4-/- mice-derived tumors, endothelial cells (ECs) failed to organize into 
tubules and were more sparsely distributed (Fig. 1H and I). These observations led us 
to conclude that the reduced tumor growth in Sdc4-/- mice was primarily a result of 
defective tumor vascularization and not due to any inherent differences between WT 
and Sdc4-/- mouse immune responses.  
 
2.2.2 Pathological angiogenesis in the eye is impaired in Sdc4-/- animals 
Having established that tumor angiogenesis was impaired in Sdc4-/- mice, we next 
tested whether other pathological angiogenic responses were affected in these animals. 
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Oxygen-induced retinopathy (OIR) is a pure hypoxia-driven, VEGFA-dependent 
angiogenesis-model that recapitulates features of diabetic retinopathy, whereas, laser-
induced choroidal neovascularization (CNV) models neovascular (‘wet’) age-related 
macular degeneration22. OIR was performed on 7 day old WT and Sdc4-/- pups by 
exposing them to hypoxia (75 % O2 for 5 days) leading to the abolition of the retinal 
vasculature, before being returned to normoxia which stimulates a neovascular 
response. After 5 days in normoxic conditions the formation of neovascular tufts 
(pathological angiogenesis) was greatly reduced (40%) in retinas of Sdc4-/- mice 
compared to WT mice (Fig. 2A and B, fig. S5A-D). Laser photocoagulation was 
performed on eyes of WT and Sdc4-/- littermates to stimulate a neovascular response 
in the choroid. Areas of CNV measured 7 days after injury by fluorescein angiography 
were significantly smaller in the eyes of Sdc4-/- mice (~75%, by lesion area) (Fig. 2C 
and D). Lesions were predominantly composed of ECs on the basis of BS1-isolectin 
staining (fig. S6A and B). 
We confirmed that the defects in this model were the result of impaired angiogenesis 
in an ex vivo model of CNV where explants of choroid/RPE tissue from WT, Sdc4+/- 
and Sdc4-/- littermates were in embedded collagen I and exposed to VEGFA. 
Significantly more angiogenic sprouts emerged from WT explants compared to Sdc4-
/- explants (Fig. 2E and F). Explants from the heterozygote (Sdc4+/-) mice exhibited 
an intermediate phenotype indicating that the angiogenic response associated with 
SDC4 is subject to gene dosage effects. This was corroborated using the aortic ring 
model of angiogenesis which also showed very limited angiogenic sprouting in Sdc4-
/-, and Sdc4+/- rings compared to WT controls (Fig. 2G). Notably, the few sprouts 
formed in the Sdc4-/- explants were immature as shown by reduced pericyte coverage 
(Fig. 2H). Together these data indicate that pathological angiogenic responses in the 
Sdc4-/- mouse are impaired. 
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2.2.3 SDC4 is upregulated during pathological angiogenesis 
Sdc4-/- mice develop normally and show no gross abnormalities19, however, no 
detailed studies have been carried out to assess whether vasculogenesis in Sdc4-/- mice 
culminates in a normal vascular network comparable to that of WT littermates. During 
the early stages of murine postnatal development angiogenesis occurs in the eye 
leading to the formation of a superficial retinal vascular plexus. In C57BL6 mice this 
occurs during the first 8 days after birth. We compared the retinal vasculature of WT, 
Sdc4+/- and Sdc4-/- neonates at P6 and observed no differences in terms of vessel 
extension (Fig. 3A and B). Although we observed a slight reduction in vascular area 
coverage, there was no difference in the number of arteries or veins in Sdc4-/- mice 
(Fig. 3C and D, fig. S7A and B). Moreover, no morphological differences were 
apparent in the microvasculature of skin, muscle or connective tissue between Sdc4-/- 
and WT adult animals (fig. S7C and D) and this was also reflected in an analysis of 
vessel heterogeneity (fig. S7D), vessel density (fig. S7E), pericyte coverage (fig. S7F) 
and vascular area in the choroid membranes (fig. S7G). Furthermore, vascular 
functionality, as measured by increased permeability in response to the vasodilator 
Bradykinin, was also unaffected in Sdc4-/- adult animals compared to WT mice (fig. 
S7H). These data suggest that Sdc4-/- mice do not exhibit any adverse phenotype 
associated with vascular development or function. To explore this further, we 
determined whether SDC4 expression was regulated during this process by measuring 
syndecan family gene expression during the development of retinal vasculature, 
comparing this profile to a situation where angiogenesis occurs in a pathological setting 
(hypoxia-induced, VEGFA-driven model). We performed quantitative rtPCR on 
retinas from P0, 4, 7, 12 and 17 neonates to measure expression of syndecans-1, -2, -3 
and -4. SDC4 gene expression remained constant in these samples (Fig. 3E). When 
pups were subjected to OIR we saw a marked increase in SDC4 gene expression in 
retinas in which neovascularization was occurring in P17 pups, when compared to the 
other 3 syndecans whose expression remained stable during the induction of 
angiogenesis (Fig. 3F).  
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To address the relevance of our findings on the role of SDC4 on pathological 
angiogenesis to human disease, the pathological retinal neovascular membranes that 
develop in human diabetic retinopathy patients were studied. Neovascular membranes 
were collected from patients suffering from type I diabetes, who had already developed 
tractional retinal detachment due to fibrosis. These samples represent the end stage of 
the disease, but still contain regions with active pathological angiogenesis. In the 
diabetic neovascular membranes SDC4 expression was evident mainly in blood vessels 
(fig. S8A). Double-staining of human tissue samples for SDC4 and either VEGFR2 (a 
marker of pathological immature blood vessels) or CD31 (a general marker of blood 
vessels) revealed that SDC4 expression was a feature of vessels which were also 
expressing VEGFR2 and not a general characteristic of the blood vessels in these 
samples (fig. S8A-C). This suggests a close association between SDC4 and VEGFR2 
on newly formed vessels in diabetic retinopathy.  
These data indicate that SDC4 is upregulated in response to pathological stimuli 
leading to neovascularization, but not during normal development of the retinal 
vasculature. To further investigate this hypothesis, we stimulated isolated primary 
murine ECs (MLECs) with the angiogenic factors VEGFA, bFGF and angiopoietin-2 
before measuring SDC4 expression. This analysis revealed a time-dependent 
upregulation of SDC4 gene transcription in response to bFGF and angiopoietin-2, 
indicating that SDC4 is upregulated in angiogenic scenarios on ECs (Fig. 3G). 
Immunofluorescence analysis on mature venules and arterioles revealed minimal 
SDC4 expression on the endothelium (fig. S9A-E). However, SDC4 was highly 
expressed on ex vivo angiogenic sprouts both on ECs (counter-stained with BS1-
isolectin) and stromal cells, possibly pericytes and smooth muscle cells, suggesting that 
SDC4 is upregulated on blood vessels during angiogenesis (Fig. 3H).  
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2.2.4 SDC4 is involved in angiogenic responses to VEGFA 
The principal driver of angiogenesis in the models described above is VEGFA7, 23 and 
we speculated that the angiogenesis defects observed in Sdc4-/- animals may be the 
result of impaired responsiveness to this protein. Therefore, WT and Sdc4-/- mice were 
injected with Matrigel containing VEGFA and bFGF in combination or separately. All 
3 conditions triggered an angiogenic response in WT mice as evidenced by plug 
vascularity. Sdc4-/- mice exhibited an identical response to bFGF but angiogenesis was 
not induced by VEGFA (Fig. 4A and 4B). This attenuated angiogenic response to 
VEGFA was confirmed using the aortic ring assay where new blood vessel sprouting 
was abolished in Sdc4-/- aortic rings in response to VEGFA but not bFGF (Fig. 4C 
and D). These data suggest that Sdc4-/- mice have a specific defect in their response 
to VEGFA-driven angiogenesis. 
We assessed whether SDC4 had a key role in VEGFA/VEGFR2 signaling in ECs. First, 
a proximity ligation assay was used to investigate whether SDC4 and VEGFR-2 
associated in a complex in ECs following VEGFA treatment. Confluent WT MLECs 
were treated with 30 ng/ml of VEGFA for 2 min or 5 min. Within 2 min of VEGFA 
treatment, SDC4/VEGFR2 complexes appeared on ECs, dissipating by 5 min (Fig. 4E 
and F). In addition, SDC4 was internalized in response to VEGFA in cells HUVECS 
expressing an HA-tagged form of SDC4 (Fig. 4G). Critically, a second assay also 
revealed that VEGFA-induced phosphorylation of VEGFR2 was markedly decreased 
in Sdc4-/- MLECs compared to WT MLECs (Fig. 4H). Flow cytometry analysis of 
lung digests confirmed that cell surface expression of VEGFR2 was the same between 
WT and Sdc4-/- lung ECs (fig. S10A and B). Taken together, this data suggests that 
SDC4 acts to facilitate VEGFR2-mediated responses to VEGFA. This has functional 
implications for VEGFR2-dependent signaling pathways; one of which is the 
promotion of VE-Cadherin internalization leading to dissociation of cell-cell contacts 
in ECs (a key step in the angiogenic process24). To examine this, wild type MLECs 
were treated with VEGFA for 5 min, whereupon VE-Cadherin disappeared from cell 
junctions and was internalized into cytoplasmic vesicles, as reported24 (fig. S11A-C). 
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In contrast, VE-Cadherin was retained in EC adherens junctions of Sdc4-/- cells 
following VEGFA treatment. Based on this we investigated VE-Cadherin expression 
in normal and OIR retinas. VE-Cadherin expression was normal in retinas at P17, but 
disrupted in OIR. Although normal VE-Cadherin expression was disrupted in some of 
the angiogenic blood vessels in Sdc4-/- retinas in OIR, the disruption was more severe 
in WT retinas. VE-Cadherin was almost totally absent from some blood vessels or was 
internalized in some of the vessels in WT retinas in OIR. These features were especially 
prominent in pre-retinal tufts that represent pathological angiogenesis in OIR (fig. 
S12). We then tested whether the decrease in VEGFR2 phosphorylation observed in ex 
vivo Sdc4-/- ECs was sufficient to affect physiological responses to VEGFA in an acute 
in vivo setting. Whereas WT and Sdc4-/- mice displayed similar levels of basal and 
bradykinin-induced vascular permeability in dorsal skin, vascular leakage induced by 
VEGFA was abolished in Sdc4-/- null mice (Fig. 4I and J).  
 
2.2.5 Targeting SDC4 has therapeutic potential 
Because our results suggest that VEGFA-driven angiogenesis requires the formation 
of a tri-molecular complex including SDC4, VEGFR2 and VEGFA on the cell surface 
of ECs, we tested the effect of the addition of soluble glycanated SDC4 ectodomain 
(solS4) to the medium of WT cells to disrupt this complex. As expected, treatment of 
primary MLECs with solS4 diminished the activation of VEGFR2 in response to 
VEGFA after 5 min (Fig. 5A and B). Disruption of VEGFA signaling by solS4 was 
also demonstrated by scratch wound cell migration assays on HUVEC monolayers. 
Cell migration was significantly enhanced by VEGFA treatment in control cells, but 
this effect was abrogated in cells treated with solS4. Consistent with our previous work 
we also saw inhibition of HUVEC cell migration in cells treated with soluble 
glycanated syndecan-2 ectodomain (solS2)16 but, unlike with solS4, VEGFA-induced 
increase in cell migration was unaffected by the treatment with solS2 (Fig. 5C) 
indicating that disruption of VEGFA responses is a characteristic specific to SDC4. 
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We also tested solS4 in the ex vivo mouse aortic ring assay of neovascularization and 
observed a strong reduction in the angiogenic response to VEGFA (Fig. 5D and E). 
Finally, we administered solS4 to mice in the laser CNV model and compared its 
effects to EYLEA, a recombinant protein corresponding to the VEGFA binding portion 
of VEGR2. Lesion formation was greatly reduced in response to both treatments 
indicating the therapeutic potential of targeting syndecan-4 (Fig. 5F and G).  
This study highlights SDC4 as a regulator of EC responses to VEGFA and loss of this 
molecule in disease model systems leads to greatly reduced angiogenesis (model 
shown in Fig. 6). These data highlight an important difference between angiogenic 
responses in disease models which require SDC4 and developmental angiogenesis in 
which SDC4 is not essential, based on the fact that no gross abnormalities are evident 
in the Sdc4-/- mouse. The existence of inflammation related regulatory elements (eg. 
NF-κB, and hypoxia response elements25) within the SDC4 promoter support the idea 
that the expression and function of this molecule is driven by responses to stress or 
injury. Based on our data and others it seems unlikely that there is redundancy between 
syndecan family members and other HSPGs during these pathological responses 
whereas maybe this is the case during development. Both SDC-1 and -2 have been 
shown to contain angiogenesis regulatory peptide sequences with their extracellular 
core proteins and these bear little homology to each other and act through distinct 
receptors. Similarly, SDC4 also contains a unique peptide sequence within its 
extracellular core protein and it is possible that this, in addition to the HS chains are 
responsible for the specificity of the interactions described here.  
We show an association between SDC4 and VEGFR2 and a rapid appearance and 
subsequent disappearance from the cell surface of both molecules in response to 
VEGFA is suggestive of a role for SDC4 in the trafficking of VEGFR2. SDC4 is known 
to be intimately associated with trafficking of integrins, most notably α5β1, and β1 
integrins are also known to complex with VEGFR2 so SDC4 may form part of a larger 
signaling nexus involving integrins and components of the VEGF signaling pathway. 
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The possibility of the involvement in this trafficking pathway of PDZ proteins, via 
interactions with the intracellular SDC4 C-terminus also cannot be excluded. 
Particularly as studies have shown a role for both syntenin and synectin (both known 
to bind SDC4) in VEGR2 trafficking and signaling. Furthermore, recent studies have 
also shown a role for SDC4 in calcium signaling and this would also be consistent with 
the defects in Ve-Cadherin redistribution we see after treatment with VEGFA.  
In this study, we used a recombinant protein corresponding to the extracellular core 
protein of SDC4 produced in mammalian cells, such that the HS chains would be 
present on this molecule, and this blocked VEGFA induced angiogenesis in both cell-
based and in vivo models. These results suggest that SDC4 blocking strategies could 
be applied in the treatment of cancer and vascular diseases where neovascularization 
is a factor and may either improve or offer an alternative to existing therapies. Since 
SDC4 only impacts neovascularization in pathological scenarios, therapeutic 
innovations targeting this molecule may have a more favorable side effect profile than 
current therapeutic options. 
 
 
 
2.3 Figures & Legends 
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2.3.2 Figure 1: Tumor angiogenesis is impaired in Sdc4-/- mice.  
(A) Papilloma formation is reduced in Sdc4-/- mice in the DBMA/TPA model. 
Micrographs of animals (left) and sections of skin (right, H&E) from WT and Sdc4-/- 
animals at week 19 (scale bar = 2 mm). (B) Number of large tumors (≥2 mm/mouse) 
over time and (C) size of papillomas at end of the experiment (n=7 mice/group). (D) 
Micrographs of B16F0 melanomas from WT and Sdc4-/- animals showing reduced 
tumor volume as quantified in (E) (n=5-6 mice/group). Levels of NK cells are equal in 
WT and Sdc4-/- animals in both spleen (F) and B16F0 tumor immune infiltrates (G) 
(n=3 mice/group). (H) Tumor vessels (arrowheads) appear in WT sections but are not 
obvious in B16F0 melanomas from Sdc4-/- mice (Ki-67, blue; CD31 red, scale bar = 
100 µM), (I) quantification of tumor vessel coverage (n=5/group, 3 images/animal). 
*P < 0.05. Error bars indicate SEM. 
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2.3.2 Figure 2: Pathological neovascularization is impaired in Sdc4-/- animals.  
(A) Micrographs showing the pre-retinal neovascularization response (stained with 
BS1-isolectin) to OIR in P17 WT neonates is greater than in equivalent Sdc4-/- animals 
(Scale bar = 500 µM). (B) Quantification of pre-retinal neovascularization (~40 
eyes/group). (C) Micrographs showing Sdc4-/- animals exhibit less angiogenesis in the 
laser induced CNV model as evident from reduced lesion area (D) (n=6-8 
animals/group, Scale bar = 2.4 mm). (E) Angiogenic sprouting is reduced in Sdc4-/- 
choroid explants, stained with BS1-Isolectin (red) and anti-αSMA (green) after 7 days 
in culture (Scale bar = 10 µM). Gene-dosage effect between WT, Sdc4+/- and Sdc4-/- 
 25 
 
(F) choroid and (G) aortic explants (n=5-6 animals/group). (H) Micrographs of aortic 
ring angiogenic sprouts showing reduced pericyte coverage on sprouts from Sdc4-/- 
rings (CD31: red, DAPI: blue, αSMA: green, Scale bar = 20 µm). *P < 0.05; **P < 
0.01; ***P<0.001; ****P<0.0001. Error bars indicate min and max values. 
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2.3.3 Figure 3: SDC4 expression is upregulated during pathological angiogenesis.  
(A) Retinas from P6 WT and Sdc4-/- neonates stained with BS1-isolectin (Scale bar = 
1 mm). (B) Vascular extension as shown by arrows in (A) is the same in WT, Sdc4+/- 
and Sdc4-/- animals (n=10-15 animal/genotype). (C) Magnified images of retinal 
vasculature (Scale bar: 100 µm) and (D) the number of vessels along a given radius is 
slightly reduced in the absence of SDC4. (E) Syndecan gene expression profile during 
early stages of murine retinal angiogenesis. SDC4 expression remains unchanged (n=5-
6) across the time course. (F) OIR induces syndecan-4 expression at day 17. Syndecan 
gene expression in neonates after OIR as compared to untreated controls. Syndecan-4 
gene expression is significantly increased on day P17 in OIR treated animals. (G) 
SDC4 gene expression increases in response to VEGFA, bFGF and ANG-2 in MLECs 
(n=3). (H) SDC4 (green) is expressed on ECs (red) on angiogenic sprouts from aortic 
rings (Scale bar = 200 μm).  *P < 0.05; **P < 0.01; ***P<0.001. Error bars indicate 
SEM in B, D, E and G and min and max values in F. 
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2.3.4 Figure 4: Defective angiogenesis in Sdc4-/- mice is due to a lack of responsiveness to 
VEGFA.  
(A and B) Matrigel plugs and (C and D) aortic rings supplemented with bFGF and 
VEGFA alone or in combination reveal Sdc4-/- tissues fail to respond to VEGFA alone 
(n=6/condition). (E) Proximity ligation assays show that SDC4 and VEGFR2 interact 
after treatment with VEGFA (Scale bar: 20 μm, 7 μm). (F) Quantification of PLA 
experiments was performed using ImageJ software (n=3, 7 images per condition). (G) 
Syndecan-4 is internalized in HUVECs after treatment with VEGFA (10 ng/ml) at the 
times indicated (Scale bar 20 µm). (H) Impaired VEGFR2 phosphorylation in Sdc4-/- 
MLECs. (I and J) Miles assay showing that VEGFA induced vascular permeability is 
impaired in Sdc4-/- mice (n=6-9 animals/group). *P < 0.05; **P < 0.01; ***P<0.001. 
Error bars indicate SEM. Comparisons made between treatments and PBS are within 
the same genotype unless otherwise indicated (bar). 
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2.3.5 Figure 5: Therapeutic potential of targeting syndecan-4 to block VEGFA induced 
pathological angiogenesis.  
(A and B) Soluble SDC4 ectodomain (solS4, 10 µg) inhibits VEGFR2 phosphorylation 
in response to VEGFA in HUVECS. (C) VEGFA-induced EC migration is inhibited 
in the presence of solS4 but not solS2. (D and E) Soluble SDC4 ectodomain inhibits 
VEGFA induced angiogenic sprout formation in a rat aortic ring assay (n=4, 5-15 
rings/condition). (F and G) SolS4 inhibits lesion formation in response to Laser 
induced CNV and its effects compare favorably to Eylea (n=6-8 animals). *P < 0.05; 
**P < 0.01; ***P<0.001. Error bars indicate SEM in B, C and G and min and max 
values in E. 
 
 
2.3.6 Figure 6: Syndecan-4 is involved in VEGFA signaling response during pathological 
angiogenesis. 
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